Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 8/2018

01-08-2018 | Review

Screening and Surveillance for Barrett’s Esophagus: Is It Cost-Effective?

Authors: John M. Inadomi, Nina Saxena

Published in: Digestive Diseases and Sciences | Issue 8/2018

Login to get access

Abstract

The cost-effectiveness of screening and surveillance for Barrett’s esophagus continues to evolve as the incidence of esophageal adenocarcinoma increases, biomarkers enhance the identification of individuals at highest risk for developing cancer, and endoscopic eradication of Barrett’s esophagus improves. Screening to detect Barrett’s esophagus may be cost-effective in selected high-risk groups based on age, race, sex and other factors such as symptoms of heartburn. Currently, endoscopic eradication therapy for Barrett’s esophagus and high-grade dysplasia is a cost-effective intervention, while endoscopic therapy for non-dysplastic Barrett’s esophagus is not a cost-effective strategy. As diagnosis of low-grade dysplasia improves, endoscopic eradication therapy may also prove to be a cost-effective intervention.
Literature
1.
Shaheen NJ, Falk GW, Iyer PG, Gerson LB. American College of G. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol.. 2016;111:30–50. quiz 51.CrossRefPubMed
2.
Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association medical position statement on the management of Barrett’s esophagus. Gastroenterology. 2011;140:1084–1091.CrossRefPubMed
3.
Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. Panel on cost-effectiveness in health and medicine. JAMA. 1996;276:1172–1177.CrossRefPubMed
4.
Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA. 1996;276:1253–1258.CrossRefPubMed
5.
Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on cost-effectiveness in health and medicine. JAMA. 1996;276:1339–1341.CrossRefPubMed
6.
Inadomi JM. Cost considerations in implementing a screening and surveillance strategy for Barrett’s oesophagus. Best Pract Res Clin Gastroenterol. 2015;29:51–63.CrossRefPubMed
7.
Gold MR. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
8.
Laureys S, Pellas F, Van Eeckhout P, et al. The locked-in syndrome: what is it like to be conscious but paralyzed and voiceless? In: Laureys S, ed. Progress in brain research, vol. 150. Amsterdam: Elsevier; 2005:495–611.
9.
Petitti DB. Meta-analysis, decision analysis, and cost-effectiveness analysis : methods for quantitative synthesis in medicine. 2nd ed. New York: Oxford University Press; 2000.
10.
Box GEP, Draper NR. Empirical model-building and response surfaces. New York: Wiley; 1987.
11.
Saxena N, Inadomi JM. Effectiveness and cost-effectiveness of endoscopic screening and surveillance. Gastrointest Endosc Clin N Am. 2017;27:397–421.CrossRefPubMed
12.
Inadomi JM, Sampliner R, Lagergren J, Lieberman D, Fendrick AM, Vakil N. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med. 2003;138:176–186.CrossRefPubMed
13.
Nietert PJ, Silverstein MD, Mokhashi MS, et al. Cost-effectiveness of screening a population with chronic gastroesophageal reflux. Gastrointest Endosc. 2003;57:311–318.CrossRefPubMed
14.
Gerson LB, Groeneveld PW, Triadafilopoulos G. Cost-effectiveness model of endoscopic screening and surveillance in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2004;2:868–879.CrossRefPubMed
15.
Rubenstein JH, Inadomi JM, Brill JV, Eisen GM. Cost utility of screening for Barrett’s esophagus with esophageal capsule endoscopy versus conventional upper endoscopy. Clin Gastroenterol Hepatol. 2007;5:312–318.CrossRefPubMed
16.
Gerson L, Lin OS. Cost-benefit analysis of capsule endoscopy compared with standard upper endoscopy for the detection of Barrett’s esophagus. Clin Gastroenterol Hepatol. 2007;5:319–325.CrossRefPubMed
17.
Gupta N, Bansal A, Wani SB, Gaddam S, Rastogi A, Sharma P. Endoscopy for upper GI cancer screening in the general population: a cost-utility analysis. Gastrointest Endosc. 2011;74:610–624. e612.CrossRefPubMed
18.
Benaglia T, Sharples LD, Fitzgerald RC, Lyratzopoulos G. Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett’s esophagus. Gastroenterology. 2013;144:62–73. e66.CrossRefPubMed
19.
Heberle CR, Omidvari AH, Ali A, et al. Cost effectiveness of screening patients with gastroesophageal reflux disease for barrett’s esophagus with a minimally invasive cell sampling device. Clin Gastroenterol Hepatol. 2017;15:1397–1404.CrossRefPubMedPubMedCentral
20.
Comay D, Blackhouse G, Goeree R, Armstrong D, Marshall JK. Photodynamic therapy for Barrett’s esophagus with high-grade dysplasia: a cost-effectiveness analysis. Can J Gastroenterol. 2007;21:217–222.CrossRefPubMedPubMedCentral
21.
Hur C, Nishioka NS, Gazelle GS. Cost-effectiveness of photodynamic therapy for treatment of Barrett’s esophagus with high grade dysplasia. Dig Dis Sci. 2003;48:1273–1283.CrossRefPubMed
22.
Shaheen NJ, Inadomi JM, Overholt BF, Sharma P. What is the best management strategy for high grade dysplasia in Barrett’s oesophagus? A cost effectiveness analysis. Gut. 2004;53:1736–1744.CrossRefPubMedPubMedCentral
23.
Vij R, Triadafilopoulos G, Owens DK, Kunz P, Sanders GD. Cost-effectiveness of photodynamic therapy for high-grade dysplasia in Barrett’s esophagus. Gastrointest Endosc. 2004;60:739–756.CrossRefPubMed
24.
Boger PC, Turner D, Roderick P, Patel P. A UK-based cost-utility analysis of radiofrequency ablation or oesophagectomy for the management of high-grade dysplasia in Barrett’s oesophagus. Aliment Pharmacol Ther. 2010;32:1332–1342.CrossRefPubMed
25.
Hu Y, Puri V, Shami VM, Stukenborg GJ, Kozower BD. Comparative effectiveness of esophagectomy versus endoscopic treatment for esophageal high-grade dysplasia. Ann Surg. 2016;263:719–726.CrossRefPubMed
26.
Hur C, Choi SE, Rubenstein JH, et al. The cost effectiveness of radiofrequency ablation for Barrett’s esophagus. Gastroenterology. 2012;143:567–575.CrossRefPubMedPubMedCentral
27.
Inadomi JM, Somsouk M, Madanick RD, Thomas JP, Shaheen NJ. A cost-utility analysis of ablative therapy for Barrett’s esophagus. Gastroenterology. 2009;136:2101–2114. e2101–2106.CrossRefPubMedPubMedCentral
28.
Pohl H, Sonnenberg A, Strobel S, Eckardt A, Rosch T. Endoscopic versus surgical therapy for early cancer in Barrett’s esophagus: a decision analysis. Gastrointest Endosc. 2009;70:623–631.CrossRefPubMed
29.
Yousef F, Cardwell C, Cantwell MM, Galway K, Johnston BT, Murray L. The incidence of esophageal cancer and high-grade dysplasia in Barrett’s esophagus: a systematic review and meta-analysis. Am J Epidemiol. 2008;168:237–249.CrossRefPubMed
30.
von Rahden BH, Stein HJ, Weber A, et al. Critical reappraisal of current surveillance strategies for Barrett’s esophagus: analysis of a large German Barrett’s database. Dis Esophagus. 2008;21:685–689.CrossRef
31.
Sharma P, Falk GW, Weston AP, Reker D, Johnston M, Sampliner RE. Dysplasia and cancer in a large multicenter cohort of patients with Barrett’s esophagus. Clin Gastroenterol Hepatol. 2006;4:566–572.CrossRefPubMed
32.
Wani S, Falk GW, Post J, et al. Risk factors for progression of low-grade dysplasia in patients with Barrett’s esophagus. Gastroenterology. 2011;141:U1179–U1590.CrossRef
33.
Alikhan M, Rex D, Khan A, Rahmani E, Cummings O, Ulbright TM. Variable pathologic interpretation of columnar lined esophagus by general pathologists in community practice. Gastrointest Endosc. 1999;50:23–26.CrossRefPubMed
34.
Reid BJ, Haggitt RC, Rubin CE, et al. Observer variation in the diagnosis of dysplasia in Barrett’s esophagus. Hum Pathol. 1988;19:166–178.CrossRefPubMed
35.
Kastelein F, van Olphen S, Steyerberg EW, et al. Surveillance in patients with long-segment Barrett’s oesophagus: a cost-effectiveness analysis. Gut. 2015;64:864–871.CrossRefPubMed
36.
Guarner-Argente C, Buoncristiano T, Furth EE, Falk GW, Ginsberg GG. Long-term outcomes of patients with Barrett’s esophagus and high-grade dysplasia or early cancer treated with endoluminal therapies with intention to complete eradication. Gastrointest Endosc. 2013;77:190–199.CrossRefPubMed
37.
Bhat S, Coleman HG, Yousef F, et al. Risk of malignant progression in Barrett’s esophagus patients: results from a large population-based study. J Natl Cancer Inst. 2011;103:1049–1057.CrossRefPubMedPubMedCentral
38.
de Jonge PJ, van Blankenstein M, Looman CW, Casparie MK, Meijer GA, Kuipers EJ. Risk of malignant progression in patients with Barrett’s oesophagus: a Dutch nationwide cohort study. Gut. 2010;59:1030–1036.CrossRefPubMed
39.
Hvid-Jensen F, Pedersen L, Drewes AM, Sorensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med. 2011;365:1375–1383.CrossRefPubMed
40.
Sikkema M, de Jonge PJ, Steyerberg EW, Kuipers EJ. Risk of esophageal adenocarcinoma and mortality in patients with Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2010;8:235–244. quiz e232.CrossRefPubMed
41.
Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol. 2001;32:368–378.CrossRefPubMed
42.
di Pietro M, Alzoubaidi D, Fitzgerald RC. Barrett’s Esophagus and cancer risk: how research advances can impact clinical practice. Gut Liver. 2014;8:356–370.CrossRefPubMedPubMedCentral
43.
Rubenstein JH, Vakil N, Inadomi JM. The cost-effectiveness of biomarkers for predicting the development of oesophageal adenocarcinoma. Aliment Pharmacol Ther. 2005;22:135–146.CrossRefPubMed
44.
Wong DJ, Paulson TG, Prevo LJ, et al. p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett’s metaplastic epithelium. Cancer Res. 2001;61:8284–8289.PubMed
45.
Alvi MA, Liu X, O’Donovan M, et al. DNA methylation as an adjunct to histopathology to detect prevalent, inconspicuous dysplasia and early-stage neoplasia in Barrett’s esophagus. Clin Cancer Res. 2013;19:878–888.CrossRefPubMed
46.
Jin Z, Cheng Y, Gu W, et al. A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett’s esophagus. Cancer Res. 2009;69:4112–4115.CrossRefPubMedPubMedCentral
47.
Kaz AM, Wong CJ, Luo Y, et al. DNA methylation profiling in Barrett’s esophagus and esophageal adenocarcinoma reveals unique methylation signatures and molecular subclasses. Epigenetics. 2011;6:1403–1412.CrossRefPubMedPubMedCentral
48.
Dulak AM, Stojanov P, Peng S, et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet. 2013;45:478–486.CrossRefPubMedPubMedCentral
49.
Kadri SR, Lao-Sirieix P, O’Donovan M, et al. Acceptability and accuracy of a non-endoscopic screening test for Barrett’s oesophagus in primary care: cohort study. BMJ. 2010;341:c4372.CrossRefPubMedPubMedCentral
50.
Reid BJ, Prevo LJ, Galipeau PC, et al. Predictors of progression in Barrett’s esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol. 2001;96:2839–2848.CrossRefPubMedPubMedCentral
51.
Rabinovitch PS, Longton G, Blount PL, Levine DS, Reid BJ. Predictors of progression in Barrett’s esophagus III: baseline flow cytometric variables. Am J Gastroenterol. 2001;96:3071–3083.CrossRefPubMedPubMedCentral
52.
Galipeau PC, Li X, Blount PL, et al. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med. 2007;4:e67.CrossRefPubMedPubMedCentral
53.
Gordon LG, Mayne GC, Hirst NG, et al. Cost-effectiveness of endoscopic surveillance of non-dysplastic Barrett’s esophagus. Gastrointest Endosc.. 2014;79:242–256. e246.CrossRefPubMed
54.
Hur C, Nishioka NS, Gazelle GS. Cost-effectiveness of aspirin chemoprevention for Barrett’s esophagus. J Natl Cancer Inst. 2004;96:316–325.CrossRefPubMed
55.
Choi SE, Perzan KE, Tramontano AC, Kong CY, Hur C. Statins and aspirin for chemoprevention in Barrett’s esophagus: results of a cost-effectiveness analysis. Cancer Prev Res (Phila). 2014;7:341–350.CrossRef
56.
Sonnenberg A, Fennerty MB. Medical decision analysis of chemoprevention against esophageal adenocarcinoma. Gastroenterology. 2003;124:1758–1766.CrossRefPubMed
57.
Das A, Wells C, Kim HJ, Fleischer DE, Crowell MD, Sharma VK. An economic analysis of endoscopic ablative therapy for management of nondysplastic Barrett’s esophagus. Endoscopy. 2009;41:400–408.CrossRefPubMed
Metadata
Title
Screening and Surveillance for Barrett’s Esophagus: Is It Cost-Effective?
Authors
John M. Inadomi
Nina Saxena
Publication date
01-08-2018
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 8/2018
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-018-5148-7

Other articles of this Issue 8/2018

Digestive Diseases and Sciences 8/2018 Go to the issue

Review

How Should We Report Endoscopic Results in Patient’s with Barrett’s Esophagus?

Editorial

A Goblet (Cell) Half Full: What Do We Really Know About Barrett’s Esophagus—A Tribute to Emmet Keeffe

Review

Origins of Metaplasia in the Esophagus: Is This a GE Junction Stem Cell Disease?

Review

Management of Early-Stage Adenocarcinoma of the Esophagus: Endoscopic Mucosal Resection and Endoscopic Submucosal Dissection

Review

Biomarkers of Barrett’s Esophagus: From the Laboratory to Clinical Practice

Review

Are Gastric and Esophageal Metaplasia Relatives? The Case for Barrett’s Stemming from SPEM

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits